Katie Dahlstrom

Katie Dahlstrom is Vice President of Clinical Development Operations at Theseus Pharmaceuticals. Katie was previously a Senior Director of Clinical Operations at Agios Pharmaceuticals where she oversaw the operational execution of the TIBSOVO® (ivosidenib) program from IND through full approval from a Phase 1 clinical trial in R/R acute myeloid leukemia (AML), including a successful FDA inspection with no 483s. She also oversaw the successful execution of Phase 3 pivotal trials with mitapivat and was the Clinical Operations lead on the subsequent NDA/MAA filings in a rare hematologic disorder, pyruvate kinase deficiency, as well as clinical development planning and startup of pivotal programs in thalassemia and sickle cell disease. Katie has prior clinical operations experience from Takeda Oncology and pharmacovigilance experience from Genzyme, a Sanofi Company. Katie received a B.S. in Biology from Stonehill College and an M.A. in Clinical Investigation from Boston University Medical School.